Regulation of expression of cytokines and growth factors in osteoarthritic cartilage explants

Clinical Rheumatology

Volumn 20, Issue 5, 2001, Pages 353-358

  Moos, V ^a   Sieper, J ^a   Herzog, V ^a   Muller B ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

Chondrocytes; Cytokines; Osteoarthritis

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; RECOMBINANT CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE MATRIX; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; EXPLANT; EXTRACELLULAR MATRIX; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; IN VITRO STUDY; MALE; OSTEOARTHRITIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; STAINING; STIMULATION; TISSUE CULTURE;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CARTILAGE, ARTICULAR; CULTURE TECHNIQUES; CYTOKINES; DOWN-REGULATION; FEMALE; GROWTH SUBSTANCES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-6; MALE; MIDDLE AGED; OSTEOARTHRITIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0034789024     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670170025     Document Type: Article

References (26)

1. Cytokines in osteoarthritis: Mediators or markers of joint destruction?
2. Growth factor responsiveness of human articular chondrocytes: Distinct profiles in primary chondrocytes, subcultured chondrocytes and fibroblasts
3. Degenerative and repair responses of cartilage to cytokines and growth factors occur via distinct pathways
4. Transforming growth factor-beta 1 stimulates synthesis of proteoglycan aggregates in calf articular cartilage organ cultures
5. Insulin-like growth factor stimulation of chondrocyte proteoglycan synthesis by human synovial fluid
6. Joint inflammation and cartilage destruction may occur uncoupled
7. Transforming growth factor beta 1 regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular chondrocytes
8. Transforming growth factor-beta inhibition of interleukin-1 activity involves down-regulation of interleukin-1 receptors on chondrocytes
9. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4
10. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10
11. Immunohistochemical analysis of cytokine expression in human osteoarthritic and healthy cartilage
12. Role of cytokines in rheumatoid arthritis
13. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage
14. The natural history of the anterior cruciate ligament-deficient knee. Changes in synovial fluid cytokine and keratan sulfate concentrations
15. Synovial fluid cytokine concentrations as possible prognostic indicators in the ACL-deficient knee
16. Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose
17. Role of TNF alpha, in relation to IL-1 and IL-6 in the proteoglycan turnover of human articular cartilage
18. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice
19. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion
20. TNF2, a polymorphism of the tumour necrosis-alpha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype
21. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease
22. Possible genetic association between interleukin-1alpha gene polymorphism and the severity of chronic polyarthritis
23. Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use
24. Early rheumatoid arthritis. Future treatment
25. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
26. In vivo suppression of early experimental osteoarthritis by interleukin- 1 receptor antagonist using gene therapy